Телаванцин — новый препарат, активный против полирезистентных грамположительных возбудителей. Клинические и микробиологические аспекты в вопросах и ответах | КМАХ

Телаванцин — новый препарат, активный против полирезистентных грамположительных возбудителей. Клинические и микробиологические аспекты в вопросах и ответах

Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(2):127-145

​ Дехнич А.В., Зубарева Н.А., Козлов Р.С., Попов Д.А., Романов А.В., Руднов В.А.
телаванцин гликопептиды MRSA инфекции кожи и мягких тканей нозокомиальная пневмония инфекции кровотока
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(2):127-145

Аннотация

Телаванцин — первый представитель нового поколения гликопептидных антибиотиков — полусинтетических липогликопептидов. Препарат используется для терапии нозокомиальной пневмонии, включая вентилятор-ассоциированную пневмонию, и инфекций кожи и мягких тканей, вызванных грам(+) бактериями, в том числе с полирезистентностью к антибиотикам. Ещё одной перспективной сферой применения телаванцина являются грам(+) инфекции кровотока — бактериемия и инфекционный эндокардит. Препарат активен в отношении широкого спектра аэробных и анаэробных грам(+) бактерий, в том числе устойчивых к другим антибиотикам. В спектр его действия входят: метициллинорезистентные штаммы Staphylococcus aureus и коагулазонегативных стафилококков, штаммы S. aureus со сниженной чувствительностью к ванкомицину (VISA) и даптомицину, пенициллинорезистентные штаммы Streptococcus pneumoniae, ампициллинорезистентные штаммы энтерококков и штаммы энтерококков с VanB фенотипом устойчивости к ванкомицину. Телаванцин обладает быстрым бактерицидным эффектом за счёт двойного механизма действия, активен в отношении внуклеточно расположенных бактерий и микробных биоплёнок. В статье приведены современные данные in vitro, in vivo и клинических исследований телаванцина, а также информация об особенностях клинического применения данного препарата.

Дехнич Андрей Владимирович

Научно-исследовательский институт антимикробной химиотерапии ГБОУ ВПО СГМУ Минздрава России, Смоленск, Россия

Зубарева Н.А.

ГБОУ ВПО «Пермский государственный медицинский университет» Минздрава России, Пермь, Россия

Козлов Роман Сергеевич

Научно-исследовательский институт антимикробной химиотерапии ГБОУ ВПО СГМУ Минздрава России, Смоленск, Россия

Попов Дмитрий Александрович

ФГБНУ «Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева», Москва, Россия

Романов Андрей Вячеславович

Научно-исследовательский институт антимикробной химиотерапии ГБОУ ВПО СГМУ Минздрава России, Смоленск, Россия

Руднов Владимир Александрович

ГБОУ ВПО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург, Россия

  • 1. Bryskier A. Glycopeptides and lipoglycopeptides. In: Bryskier A. editor Antimicrobial Agents. ASM Press, Washington, DC. 2005.
  • 2. Leadbetter M.R., Adams S.M., Bazzini B., et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo). 2004 May; 57(5):326-36.
  • 3. Butler M.S., Hansford K.A., Blaskovich M., Halai R., Cooper M.A. Glycopeptide antibiotics: Back to the future. The Journal of Antibiotics 2014:1-14
  • 4. Higgins D. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127-34.
  • 5. Lunde C.S., et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor Lipid II. Antimicrob Agents Chemother 2009; 53:3375-83.
  • 6. Trevino J., et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chem Eur J 2014; 20:7363-72.
  • 7. Beauregard D.A., Williams D.H., Gwynn M.N., Knowles D. J. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 1995; 39:781-5.
  • 8. Draghi D.C., Jones M.E., Flamm R.K., Thornsberry C., Sahm D.F. Telavancin activity against current and diverse populations of enterococci and Streptococcus pneumoniae. Presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2005, Washington, DC.
  • 9. Mendes R.E., Sader H.S., Farrell D.J., Jones R.N. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 2012; 56:3999-4004.
  • 10. Song Y., Lunde C.S., Benton B.M., Wilkinson B.J. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob Agents Chemother 2012; 56: 3157-64.
  • 11. Eliopoulos G.M., Wennersten C.B., Sakoulas G., Moellering R.C. In vitro bactericidal activity of telavancin against S. aureus with relative tolerance to vancomycin. Presented at the 44th Annual International Conference on Antimicrobial Agents and Chemotherapy, October 30- November 2, 2004, Washington, DC.
  • 12. Madrigal A.G., Basuino L., Chambers H.F. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-5.
  • 13. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Grampositive clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:2383-8.
  • 14. Jansen W.T., Verel A., Verhoef J., Milatovic D. In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007; 51:3420-3424.
  • 15. Farrell D.J., Mendes R.E., Rhomberg P.R., Jones R.N. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 2014; 58:5547-51.
  • 16. Mendes R.E., Farrell D.J., Sader H.S., Streit J.M., Jones R.N. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagnostic Microbiology and Infectious Disease 2015; 81:275-9.
  • 17. Leuthner K.D., Cheung C.M., Rybak M.J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycinresistant Staphylococcus aureus. J Antimicrob Chemother. 2006 Aug;58(2):338-43.
  • 18. Pace J.L., Krause K., Johnston D., et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602-4.
  • 19. Barcia-Macay M., Lemaire S., Mingeot-Leclercq M.P., Tulkens P.M., Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycinresistant Staphyloccus aureus. J Antimicrob Chemother 2006; 58:1177-84.
  • 20. Hegde S.S., Reyes N., Wiens T., et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-50.
  • 21. Odenholt I., Lowdin E., Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother 2007; 51:3311-6.
  • 22. Reyes N., Skinner R., Benton B.M., et al. Efficacy of telavancin in amurine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:462-5.
  • 23. Hegde S.S., Difuntorum S., Skinner R., Trumbull J., Krause K.M. Efficacy of telavancin agasint glycopeptidesintermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 2009; 63:763-6.
  • 24. Reyes N., Skinner R., Kaniga K., et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:4344-6.
  • 25. Madrigal A.G., Basuino L., Chambers H.F. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-5.
  • 26. Clouse F.L., Hovde L.B., Rotschaffer J.C. In vitro evaluation of the activities of telavancin, cefazolin and vancomycin against methicillinsusceptible and methicillin resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 2007; 51:4521-4.
  • 27. Higgins D.L., Chang R., Debabov D.V., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 29:1127-34.
  • 28. Leonard S.N., Rybak M.J. Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram-Positive Infections. Pharmacotherapy 2008; 28(4):458-68.
  • 29. Lunde C.S., Hartouni S.R., Janc J.W., Mammen M., Humphrey P. P. , Benton B.M. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009; 53:3375-83.
  • 30. King A., Phillips I., Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53:797-803.
  • 31. Pace J.L., Krause K., Johnston D., et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602-4.
  • 32. Barcia-Macay M., Mouaden F., Mingeot-Leclercq M., Tulkens P.M., Van Bambeke F. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). Journal of Antimicrobial Chemotherapy 2008; 61:1288- 94.
  • 33. Gander S., Kinnaird A., Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 2005; 56:337-43.
  • 34. LaPlante K.L., Mermel L.A. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother 2009; 53:3166-9.
  • 35. Sahm D.F., Benton B.M., Cohen M.A., et al. Telavancin demonstrates a low potential for in vitro selection of resistance among key target grampositive species. Paper presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2006 Sep.
  • 36. Lunde C.S., Hartouni S.R., Janc J.W., e. a. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009; 53(8):3375-83.
  • 37. Krause K.M., Benton B.M., Higgins D.L., et al. Telavancin possesses low potential for resistant mutant selection in serial passage studies of Staphylococcus aureus and enterococci. Paper presented at 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark; 2005 Apr.
  • 38. Quality Control table v 5.0. Available at URL: www.eucast.org
  • 39. Clinical and Laboratory Standards Institute. M100S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Forth Informational Supplement. 2015.
  • 40. The European Committee on Antimicrobial Susceptibility Testing — EUCAST. Clinical breakpoints — bacteria (v 5.0). Available at URL: http://www.eucast.org/clinical_breakpoints/
  • 41. Dunne M.W., Sahm D., Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob 2015; 14(1):19.
  • 42. Shaw J.P. , Seroogy J., Kaniga K., et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005; 49:195-201.
  • 43. Wong S.L., Barriere S.L., Kitt M.M., Goldberg M.R. Multiple dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008; 62:780-3.
  • 44. Sun H.K., Duchin K., Nightengale C.H., et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006; 50:788-90.
  • 45. Gotfried M.H., Shaw J.P. , Benton B.M., et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008; 52:92-7.
  • 46. LodiseT.P. , Gotfried M., Barriere S., Drusano G.L Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008; 52:2300-4.
  • 47. Duchin K., Shaw J., Seroogy J., et al. Single dose pharmacokinetics of telavancin in subjects with renal dysfunction [abstract p1028]. In: Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Disease (Prague, Czech Republic). 2004.
  • 48. Duchin K., Shaw J., Seroogy J., et al. Effect of hemodialysis on single dose pharmacokinetics of telavancin [abstract P 897]. In: Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Disease (Copenhagen, Denmark). 2005.
  • 49. Patel J.H., Grio M.C, Churchwell M.D., Seroogy J., Barriere S., Mueller B.A. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration [abstract p1539]. In: Program and abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (Nice, France). 2007.
  • 50. Wong S.L., Shaw J.P. , Barriere S.L., et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment [abstract A-1951]. In program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). 2006.
  • 51. Corey G.R., Kollef M.H., Shorr A.F., et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-7.
  • 52. Dunbar L.M., Tang D.M., Manausa R.M. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Therapeutics and Clinical Risk Management 2008: 4(1) 235-44.
  • 53. Rubinstein E., Lalani T., Corey G.R., et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Grampositive pathogens. Clin Infect Dis 2011; 52:31- 40.
  • 54. Rubinstein E., Cammarata S., Oliphant T., Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, doubleblind, multicenter study. Clin Infect Dis 2001; 32:402-12.
  • 55. Wunderink R.G., Cammarata S.K., Oliphant T.H., Kollef M.H. Continuation of a randomized, doubleblind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
  • 56. Wunderink R.G., Rello J., Cammarata S.K., CroosDabrera R.V., Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
  • 57. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
  • 58. Telavancin summary of product characteristics (EU). First issued 2 September 2011. http://www.ema.europa.eu/docs/enGB/documentlibrary/EPAR—ProductInformation/human/001240/WC500115364.pdf [accessed 8 May 2014].
  • 59. Torres A., Rubinstein E., Corey3 G.R., Stryjewski M.E., Barriere S.L. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother 2014; 69:1119-26.
  • 60. Stryjewski M.E., O’Riordan W.D., Lau W.K., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to grampositive bacteria. Clin Infect Dis 2005; 40:1601-7.
  • 61. Stryjewski M.E., Chu V.H., O’Riordan W.D., et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862-7.
  • 62. Stryjewski M.E., Graham D.R., Wilson S.E., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-93.
  • 63. Nnedu O.N., Pankey G.A. Update on the emerging role of telavancin in hospital-acquired infections. Therapeutics and Clinical Risk Management 2015; 11:605-10.
  • 64. Barriere S.L., Farrell D.J., Rhomberg P. R., Jones R.N. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis 2014; 80:327-9.
  • 65. Corey G.R., Rubinstein E., Stryjewski M.E., Bassetti M., Barriere S.L. Potential role for telavancin in bacteremic infections due to Gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 2015; 60:787-96.
  • 66. Barriere S.L. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol 2010; 5:1765-73. Keynan Y., Rubinstein E. Telavancin in the treatment of invasive Gram-positive infections. Clinical Audit 2012; 4:25-9.
  • 67. Stryjewski M.E., Lentnek A., O’Riordan W., et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.
  • 68. Chaftari A., Hachem R., Jordan M., et al. Evaluation of telavancin in the treatment of Gram-positive bloodstream infections in cancer patients. Poster presented at: IDWeek; October 8-12, 2014; Philadelphia, PA.
  • 69. Madrigal A.G., Basuino L., Chambers H.F. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3163-5.
  • 70. Mirу J.M., Garcнa-de-la-Mаria C., Armero Y., et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:2373-7.
  • 71. Nace H., Lorber B. Successful treatment of methicillinresistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010; 65:1315-6.
  • 72. Marcos L.A., Camins B.C. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010; 54:5376-8.
  • 73. Joson J., Grover C., Downer C., Pujar T., Heidari A. Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. J Antimicrob Chemother 2011; 66:2186-8.
  • 74. Polyzos K.A., Mavros M.N., Vardakas K.Z., Makris M.C., Rafailidis P.I., Falagas M.E. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 2012; 7(8):e41870.
  • 75. Corey G.R., Kollef M.H., Shorr A.F., et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother 2014; 58:2030-7.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились